Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Brief Report

COVID-19 vaccination hesitancy among Americans with disabilities aged 18-65: An exploratory analysis

Andrew Myers, MA *, Catherine Ipsen, MA, PhD, Ari Lissau, BA

University of Montana, Rural Institute for Inclusive Communities, Missoula, MT, 59812, USA

ABSTRACT

Background: It is important for people with disabilities to be vaccinated against COVID-19 because, as a group, they are at increased risk of severe outcomes. While there are multiple vaccines available to prevent COVID-19, a considerable proportion of Americans report some hesitancy to becoming vaccinated, including people with disabilities.

Objective: We conducted a study to explore what factors may contribute to COVID-19 vaccination hesitancy among Americans with disabilities.

Methods: We used Amazon’s Mechanical Turk to survey 439 people with disabilities (ages 18-65) about their concerns of the COVID-19 disease, vaccines, and hesitancy toward vaccination to learn more about factors that influence vaccination hesitancy. Concerns about vaccines were analyzed as a composite variable representing different dimensions such as: side effects, too new, developed too quickly, influenced by politics, and effectiveness.

Results: Results from a logistic regression indicate that concern about vaccines was the most significant predictor of hesitancy, even after considering demographic, economic, and geographic factors. Concerns about getting COVID-19, getting tested for COVID-19, trust in experts, education, and being a Democrat were negatively associated with hesitancy.

Conclusions: These findings indicate that some groups of individuals may be more vaccination hesitant because they are more concerned about vaccine safety than COVID-19 infection. Public health messaging that focuses on the risks of vaccines relative to the risks of COVID-19 might be one strategy to reduce hesitancy and increase vaccination uptake. Messaging should also be tailored to specific disabilities (i.e. physical, mental, sensory), written in plain language, and disseminated in accessible formats.

© 2021 Elsevier Inc. All rights reserved.
sclerosis. Addressing this knowledge gap is critical to ensuring that people with disabilities are considered in current and future vaccination efforts. Understanding which factors impact vaccination hesitancy is critical for crafting health messaging, creating accommodations, and planning and implementing vaccination programs.

We conducted a study to explore what factors may contribute to COVID-19 vaccination hesitancy among people with disabilities across the U.S. Based on prior studies, we hypothesized that females, Black adults, rural residents, Republicans, and concerns about the safety of vaccines would be positively associated with COVID-19 vaccination hesitancy, while trust in experts, having a college degree, getting tested for COVID-19, and concerns about getting sick from COVID-19 would be negatively associated.

Methods

Procedures

We recruited 439 people with disabilities from 47 U.S. states via Amazon’s Mechanical Turk (MTurk) to complete an online survey. MTurk is a crowdsourced marketplace where requesters post “Human Intelligence Tasks” (HITs) that workers complete for payment. For surveys, screening questions can be used to select a specific population, who are then invited to participate.

A total of 3071 MTurk workers completed a 10-item screening questionnaire, and were paid $2.55. Individuals who met screening criteria (i.e., lived in the U.S., self-reported disability, aged 18+) were recruited to complete the survey and were paid a $3.00 bonus. All data were collected between February 11–28, 2021, approximately two months after the Pfizer-BioNTech and Moderna COVID-19 vaccines became available for high-risk individuals (e.g., healthcare workers, residents in long-term care facilities, older adults, some minority groups, and individuals with certain health conditions).

To minimize false reporting, we employed data quality guidance outlined by MTurk researchers, including hidden screening criteria, MTurk approval ratings, and cognitive checks. In order to access the screening questionnaire, workers had to meet a 95% approval rating based on past MTurk performance. The screening questionnaire contained two cognitive questions to prevent computer bots from taking the survey. To obscure our target population and reduce response bias, additional screening criteria were included but excluded from data collection. We used two disability screening questions from the National Survey on Health and Disability (NSHD) to identify people with disabilities: “Are you limited in any way in any activities because of a physical, mental or emotional problem?” and “Do you now have any health problem that requires you to use special equipment, such as a cane, a wheelchair, a special bed, or a special telephone?” Respondents who endorsed either of these items were recruited into the survey. We also utilized an additional question to oversample rural respondents (county with an urban core of 49,999 or less).

Measures

Vaccination hesitancy. We asked about current vaccination status (yes/no). For those who were not vaccinated, we asked if they “want to get the free COVID-19 vaccine, when it becomes available?” using a 5-point Likert-type scale (1 = definitely yes to 5 = definitely no). We constructed a dichotomous vaccination hesitancy variable from these responses, where individuals who responded “unsure,” “probably no,” or “definitely no” were coded as hesitant.

Concerns about COVID-19 vaccines. Respondents rated agreement with statements about COVID-19 vaccine concerns on a 7-point Likert-type scale (1 = strongly disagree to 7 = strongly agree). Statements included: “I’m worried about adverse side effects from a COVID-19 vaccine,” “I think the COVID-19 vaccines were developed too quickly,” “I think the COVID-19 vaccines are too new,” “I think politics influenced the development of the COVID-19 vaccines,” “I think the COVID-19 vaccines will be effective.” We reverse coded the item about effectiveness, summed respondent scores across all questions, and divided by five to create a composite variable representing average concern about the COVID-19 vaccines.

Concerns about COVID-19 disease. Respondents rated level of concern on two items using a 7-point Likert-type scale (1 = strongly disagree to 7 = strongly agree) including: “I’m worried about getting sick from the COVID-19 virus” and “I’m worried about people around me getting sick from the COVID-19 virus.” We summed respondent scores and divided by two to create an average concern about COVID-19 disease variable.

Tested for COVID-19. Respondents indicated if they had been tested for COVID-19 in the last 7 days (yes/no).

Trust in experts. Respondents rated their trust of various information sources on the COVID-19 vaccines, using a 7-point Likert-type scale from 1 = total distrust to 5 = total trust. Information source categories were based on literature and about trust in public health recommendations from (1) personal contacts (e.g., family, friends, neighbors), (2) service providers (e.g., physicians, case managers), (3) local news, (4) national news, (5) local county/state agencies (e.g. county health departments), (6) federal agencies (e.g., CDC), and (7) Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases. We used factor analysis to examine variability across information sources, and created a composite “trust in experts” variable by summing trust ratings among “service providers,” “local county/state agencies,” “federal agencies,” and “Dr. Anthony Fauci.”

Health literacy. We used the single item literacy screener (SILS) to assess health literacy. The measure assesses reading ability as a component of health literacy, and asks: “How often do you need to have someone help you when you read instructions, pamphlets, or other written material from your doctor or pharmacy?” (1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always). A higher score on the SILS indicates lower levels of health literacy.

Demographics. Demographic questions included gender, age, race/ethnicity, education, employment, and income. We constructed variables for employment status coded as “not employed” or “employed” and education coded as “bachelor’s degree or higher” and “no bachelor’s degree.” We split income categories by the median, and created two groups: $40,000 or less” and “$40,001 or higher.”

Political party. All respondents were asked: “Do you consider yourself: Democrat, Republican, independent, or other?”

Rural and urban classifications. Respondents provided county and state residence. We matched responses to Federal Informational Processing Standard county codes, and used the Office of Management and Budget (OMB) guidelines to classify residence as urban (containing an urban core of 50,000 or more) or rural (containing an urban core of 49,999 or less).

Health conditions. We asked about underlying health conditions the CDC recommended for prioritization in vaccination plans: cancer, chronic kidney disease, chronic lung disease, down syndrome, sickle cell disease, heart condition, asthma, diabetes, cereburovascular disease, severe obesity, immunodeficiency, autoimmune disease, HIV/AIDS, cystic fibrosis, liver disease, pulmonary fibrosis, thalassemia, neurological conditions, hypertension/high blood pressure, and chronic obstructive pulmonary disease (COPD). Anyone indicating at least one of these conditions...
was coded has having a health condition.

Disability. In addition to screening questions, we included the Washington Group Short Set (WGSS) to gain a more comprehensive view of disability status. Respondents used a 4-point Likert-type scale (1 = no difficulty to 4 = cannot do at all) to indicate their difficulty “because of a health problem”: (1) seeing, even if wearing glasses, (2) hearing, even if using a hearing aid, (3) walking or climbing steps, (4) remembering or concentrating, (5) self-care, and (6) communicating. We analyzed these dichotomously (any difficulty vs. no difficulty).

Analyses

We compared continuous variables with t-tests, ANOVAs, and Pearson’s correlations, and categorical variables using Chi-square tests with Bonferroni corrections for post-hoc tests. We also used a logistic regression to estimate the odds of COVID-19 vaccination hesitancy among respondents. Correlations between variables included in the regression did not indicate multi-collinearity.

Sample

Respondents were aged 18–34 (48%), 35–64 (47%), and 65+ (5%). They were female (49%), male (50%) and other gender (1%). Respondents were White (74%), Asian (7.5%), Black (5%), American Indian/Alaska Native (2%), Native Hawaiian/Pacific Islander (0.5%), other race (1%), and approximately 10% reported Hispanic ethnicity of any race. Respondents were employed (72%), had a bachelor’s degree or higher (53%) and were from urban locations (78%). Respondents were Democrat (44%), Republican (26%), independent (25%), or other political party (5%).

Results

Disability and health conditions

Respondents reported various types of disabilities and health conditions that increased risk of severe outcomes from COVID-19. Over 85% of respondents reported at least one WGSS disability: seeing (43%), hearing (23%), walking or climbing steps (50%), remembering or concentrating (57%), self-care (31%), and communicating (21%). The average number of WGSS disabilities was 2.2 (ranging 0–6), with 34% reporting three or more. Approximately 68% reported at least one health condition with an average of 1.5 (ranging 0–20). The most common health conditions were high blood pressure (21%), asthma (20%), and diabetes (18%).

Concerns about COVID-19 disease and vaccines

Table 1 compares concerns about the COVID-19 disease and vaccines for key socio-demographic groups. On average, females were more worried about side effects from a vaccine and were less likely to agree that the vaccines would be effective compared to males. Political party was also significant predictor in concerns about COVID-19 disease and COVID-19 vaccines. Specifically, Democrats reported the highest concerns about contracting or spreading COVID-19, whereas Republicans reported the highest concerns about vaccine safety. Additionally, rural residents reported more concerns about vaccines side effects, how quickly they were developed, and newness.

Hesitancy about COVID-19 vaccination

Approximately 25% of respondents indicated some hesitancy to vaccination (“unsure” = 9.8%, “probably no” = 4.8%, and “definitely no” = 10.5%). Table 2 reports the percentages of hesitancy among socio-demographic groups.

Table 3 reports the results of a logistic regression on vaccination hesitancy. Concern about vaccines was the most significant predictor of vaccination hesitancy (OR = 2.805, p < .001). Lower odds of hesitancy were associated with concern about getting sick from COVID-19 (OR = 0.713, p = .005), recently getting tested for COVID-19 (OR = 0.350, p = .044), increased trust in expert sources of information (OR = 0.780, p < .001), having a Bachelor’s degree (OR = 0.469, p = .033), and being a Democrat (OR = 0.431, p = .018). Model fit, as measured by Nagelkerke pseudo R² was 0.526, indicating strong model fit.

Discussion

Approximately 25% of our sample indicated some level of hesitancy toward COVID-19 vaccination. A KFF survey of the general US population from the same time period found that 15% definitely did not want a vaccine, 7% would get it if it was required, and 72% wanted to wait. These differences might indicate that people with disabilities were less hesitant compared to the general population during this time period. Like other research, our data indicated that females were more hesitant about getting a COVID-19 vaccine, but these results were not statistically significant when included in the regression. Rural residents were more concerned about vaccines (side effects, speed, and newness) compared to urban residents, but this did not necessarily lead to increased odds of hesitancy when included in the logistic regression. While we did observe differences of hesitancy across racial and ethnic groups, these were also not significant in the regression model. In contrast to Fisher et al. and Khubbchandani et al., who suggested low levels of health literacy may account for vaccination hesitancy, health literacy, measured as reading ability, was not a factor in our study. However, other dimensions of health literacy (e.g., numeracy or cultural/conceptual knowledge), may impact these findings. Concerns about the vaccines, concerns about COVID-19, getting tested for COVID-19, and trust in experts about COVID-19 were significant factors in in predicting the odds of vaccination hesitancy among individuals with disabilities in our study. Some characteristics were still relevant even after including these COVID-specific factors such as having a bachelor’s degree and being a Democrat.

While prior research has reported higher rates of vaccination hesitancy among some groups such as women, rural residents, and younger adults, our results may indicate that these groups could simply be more concerned about COVID-19 vaccine safety compared to concerns about getting sick from COVID-19. Both vaccines that were available during our data collection were based on mRNA technology. This technology uses genetic material from the SARS-CoV-2 virus to trigger an immune response to produce antibodies which prevent COVID-19. mRNA vaccine technology is unfamiliar to many individuals, which may explain some hesitancy and concerns about COVID-19 vaccines. Unfortunately, we did not include any questions to assess this potential factor of concern.

Hesitancy is likely compounded by inconsistent information provided by political leaders and experts. COVID-19 vaccines were developed within an impassioned and divided political climate frequently at odds with scientific guidance (e.g., Dr. Anthony Fauci). Suppression of expert voices in the public discussion of COVID-19 and vaccination, may be reflected in our findings. For example, trust in experts was associated with lower odds of vaccination hesitancy. Providing the public with direct access to expert sources of information that are culturally appropriate and understandable may be one strategy to overcoming concerns about COVID-19 vaccines and fostering vaccination uptake. This is especially
Table 1
Average concerns about COVID-19 disease and vaccines.

|                         | n   | Worried about getting COVID | Worried about contacts getting COVID | Worried about vaccine side effects | Vaccines developed too quickly | Vaccines too new | Vaccines politics influenced development | Vaccines will be effective |
|-------------------------|-----|-----------------------------|--------------------------------------|-----------------------------------|-------------------------------|------------------|------------------------------------------|----------------------------|
| Overall                 | 349 | 5.11                        | 5.6                                  | 4.77                              | 4.34                          | 4.43             | 4.91                                      | 5.3                        |
| Gender                  |     |                             |                                      |                                   |                               |                  |                                          |                            |
| Female                  | 213 | 5.08                        | 5.59                                 | 4.77                              | 4.34                          | 4.43             | 4.91                                      | 5.3                        |
| Male                    | 219 | 5.12                        | 5.6                                  | 4.58                              | 4.2                           | 4.29             | 4.77                                      | 5.54                       |
| Age                     |     |                             |                                      |                                   |                               |                  |                                          |                            |
| 18-34                   | 212 | (p = .845)                  | (p = .980)                           | (p = .033)*                        | (p = .133)                    | (p = .120)       | (p = .108)                                | (p = .002)**                |
| 35-64                   | 205 | 5.34                        | 5.6                                  | 4.71                              | 4.64                          | 4.51             | 4.55                                      | 5.07                       |
| 65+                     | 22  | 4.86                        | (5%)(p = .194)                       | (p = .337)                        | (p = .656)                    | (p = .657)       | (p = .161)                                | (p = .055)**                |
| Race/Ethnicity          |     |                             |                                      |                                   |                               |                  |                                          |                            |
| White (non-Hispanic)    | 326 | 5.52                        | 5.52                                 | 4.69                              | 4.27                          | 4.34             | 4.84                                      | 5.24                       |
| Black, AI/AN            | 34  | 5.18                        | 5.94                                 | 4.88                              | 4.44                          | 4.38             | 5.24                                      | 5.76                       |
| Hispanic (any race)     | 43  | 5.44                        | 5.72                                 | 5.02                              | 4.62                          | 5.21             | 5.16                                      | 5.6                        |
| Education Bachelor's    | 231 | 5.24                        | 5.63                                 | 4.76                              | 4.39                          | 4.52             | 4.85                                      | 5.52                       |
| No bachelor's degree    | 208 | 4.96                        | 5.57                                 | 4.77                              | 4.28                          | 4.34             | 4.97                                      | 5.06                       |
| Employment Employment   | 314 | 5.03                        | 5.54                                 | 4.89                              | 4.85                          | 4.56             | 4.99                                      | 5.27                       |
| Not employed            | 125 | 5.3                         | 5.73                                 | 4.45                              | 3.93                          | 4.11             | 4.7                                       | 5.39                       |
| Income Income less than | 216 | 5.08                        | 5.6                                  | 4.73                              | 4.31                          | 4.34             | 4.88                                      | 5.14                       |
| 40K Income over 40K     | 223 | 5.13                        | 5.6                                  | 4.8                               | 4.37                          | 4.52             | 4.93                                      | 5.45                       |
| Political Party         |     |                             |                                      |                                   |                               |                  |                                          |                            |
| Democrat                | 194 | 5.35                        | 5.84                                 | 4.53                              | 4.39                          | 4.52             | 4.66                                      | 5.66                       |
| Republican              | 115 | 5.02                        | 5.34                                 | 5.19                              | 4.96                          | 5.18             | 5.25                                      | 4.89                       |
| Independent             | 108 | 4.71                        | 5.39                                 | 4.71                              | 4.34                          | 4.99             | 5.21                                      | 4.89                       |
| Geography               |     |                             |                                      |                                   |                               |                  |                                          |                            |
| Urban                   | 341 | 5.07                        | 5.56                                 | 4.66                              | 4.21                          | 4.31             | 4.83                                      | 5.37                       |
| Rural                   | 98  | 5.22                        | 5.75                                 | 5.13                              | 4.8                           | 4.86             | 5.18                                      | 5.06                       |
| Health                  |     |                             |                                      |                                   |                               |                  |                                          |                            |
| Health condition        | 298 | 5.32                        | 5.76                                 | 4.93                              | 4.45                          | 4.55             | 4.93                                      | 5.32                       |
| No health condition     | 141 | 4.67                        | 5.27                                 | 4.43                              | 4.1                           | 4.19             | 4.86                                      | 5.26                       |

Note: Values are scaled from: 1 = “strongly disagree,” 4 = “neither,” 7 = “strongly agree.” We report the mean value for each group listed. *p ≤ .05, **p ≤ .01, ***p ≤ .001. ab Different letters indicate post-hoc values significantly differ within variables that have more than two categories at p < .05 with Bonferroni adjustment.

Critical for people with disabilities because many are more likely to report conditions that put them at higher risk of experiencing a severe outcome from COVID-19.

While trust of information about COVID-19 is associated with preventive actions (i.e. wearing masks, social distancing), people with disabilities can also experience barriers to accessing public health information. Strategies to address these barriers should include translating scientific knowledge into plain language, especially for those with intellectual or developmental disabilities, providing communication through accessible formats (i.e. large print, sign language, closed captioning), and ensuring that information is available both in-person and virtual platforms. Ultimately, however, vaccination uptake relies on trust; another strategy may involve health educators and practitioners collaborating with established organizations within the disability community such as the National Council on Independent Living, the ADA National Network, TASH, or the American Association of People with Disabilities, among many others.

Limitations

A primary limitation of this study is reliance on the MTurk platform for data collection. While MTurk is a valuable recruitment strategy for hard-to-reach populations, including those with...
Note: Vaccination hesitancy was analyzed as a binary variable where responses including "unsure," "probably no," and "definitely no" were coded as hesitant. *p ≤ .05, **p ≤ .01, ***p ≤ .001.

Table 2
Hesitancy about COVID-19 vaccination.

| Characteristic                  | Hesitant about COVID-19 Vaccination |
|---------------------------------|-------------------------------------|
| Overall                         | 25.1%                               |
| Gender (p = .002)**              |                                     |
| Female                          | 31.9%                               |
| Male                            | 18.7%                               |
| Age (p = .074)                  |                                     |
| 18-34                           | 26.4%                               |
| 35-64                           | 25.9%                               |
| 65+                             | 4.5%                                |
| Race/Ethnicity (p = .012)*      |                                     |
| White (non-Hispanic)            | 28.5%                               |
| Black, AI/AN (non-Hispanic)     | 25%                                 |
| Asian, NH/PI (non-Hispanic)     | 8.8%                                |
| Hispanic (any race)             | 11.6%                               |
| Education (p < .001)***         |                                     |
| Bachelor's degree+              | 18.2%                               |
| No bachelor's degree            | 32.7%                               |
| Employment (p = .166)           |                                     |
| Employed                        | 23.2%                               |
| Not employed                    | 29.6%                               |
| Income (p = .283)               |                                     |
| Income less than 40K            | 27.3%                               |
| Income over 40K                 | 22.9%                               |
| Political Party (p < .001)***   |                                     |
| Democrat                        | 12.4%                               |
| Republican                      | 33.9%                               |
| Independent                     | 35.2%                               |
| Geography (p = .362)            |                                     |
| Urban                           | 24%                                 |
| Rural                           | 28.6%                               |
| Health (p = .529)               |                                     |
| Health condition                | 24.2%                               |
| No health condition             | 27%                                 |

Note. Vaccination hesitancy was analyzed as a binary variable where responses including "unsure," "probably no," and "definitely no" were coded as hesitant. *p ≤ .05, **p ≤ .01, ***p ≤ .001.

Table 3
Logistic regression on COVID-19 vaccination hesitancy.

| Characteristic                  | Exp(B) | 95% CI            | Sig.   |
|---------------------------------|--------|-------------------|--------|
| Average concerns, vaccines      | 2.805  | 1.924–4.090       | <.001***|
| Average concerns, COVID-19      | .713   | .563–.902         | .005**  |
| Tested for COVID-19 (Referent: Not tested) | .350 | .126–.972 | .044* |
| Trust in experts                | .780   | .704–.863         | <.001***|
| Low health literacy             | .785   | .578–1.067        | .122    |
| Female (Referent: Not female)   | 1.889  | .957–3.729        | .067    |
| Age (Referent: 65+)             | 28.8   |                   |        |
| 18–34                           | 4.335  | .432–43.485       | .213    |
| 35–64                           | 3.318  | .342–32.195       | .301    |
| White, non-Hispanic (Referent: Not-white) | 1.870 | .833–4.200 | .129   |
| Bachelor’s degree+ (Referent: < Bachelor’s) | .469 | .235–.939 | .031*  |
| Not employed (Referent: Employed) | 1.517 | .682–3.775 | .307   |
| Income over 40K (Referent: Income <40K) | .771 | .392–1.519 | .453   |
| Democrat (Referent: Not Democrat) | .431 | .215–.863 | .018*  |
| Rural (Referent: Urban)         | .868   | .403–1.869        | .718    |
| Health condition (Referent: No condition) | 1.269 | .610–2.639 | .524   |
| Constant                        | .133   |                   | .249    |

Note. Vaccination hesitancy was analyzed as a binary variable where responses including "unsure," "probably no," and "definitely no" were coded as hesitant. *p ≤ .05, **p ≤ .01, ***p ≤ .001. Nagelkerke $R^2 = 0.526$.

Table 4

Conclusions
Overall, we found that concern about COVID-19 vaccines was associated with higher odds of hesitancy while trust in experts, getting tested for COVID-19, concern about getting COVID-19, and education were associated with lower odds of hesitancy. Addressing concerns about vaccines is critical for fostering vaccination uptake among people with disabilities, for whom severe outcomes from COVID-19 are more likely. Some strategies may include promoting better access to, and trusting in information from experts, and partnering with established disability organizations.

Funding
This research was supported by grant #90RTCP0002 from the National Institute on Disability, Independent Living, and Rehabilitation Research within the Administration on Community Living, U.S. Department of Health and Human Services.

Disclaimer
The contents and opinions expressed reflect those of the authors, and should not be considered an endorsement by the funding agency or the Federal Government.

References
1. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int. Accessed September 9, 2021.
2. CDC. COVID-19 and Your Health. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed April 13, 2021. https://www.cdc.gov/coronavirus/2019-ncov/index.html?
3. Armitage R, Nellums LB. The COVID-19 response must be disability inclusive. The Lancet Public Health. 2020;5(5):e257. https://doi.org/10.1016/S2468-2017(20)30076-1.
4. Mesa Viera C, Franco OH, Gómez Restrepo C, Abel T. COVID-19: the forgotten priorities of the pandemic. Maturitas. 2020;136:38–41. https://doi.org/10.1016/j.maturitas.2020.04.004.
5. Commissioner O of the. FDA takes key action in fight against COVID-19 By issuing emergency use authorization for first COVID-19 vaccine. FDA. Published December 14 https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19; 2020. Accessed April 13, 2021.
6. Commissioner O of the. FDA takes additional action in fight against COVID-19 By issuing emergency use authorization for second COVID-19 vaccine. FDA. Published December 21 https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid; 2020. Accessed April 13, 2021.
7. Contrera J. People with Disabilities Desperately Need the Vaccine. But States Disagree on when They’ll Get it. Washington Post. https://www.washingtonpost.com/dc-md-va/2021/01/13/disabled-coronavirus-vaccine-acceptance-in-the-US/; 2021. Accessed April 13, 2021.
8. Khubchandani J, Sharma S, Price JH, Wiblishauser MA, Sharma M, Webb FJ. COVID-19 vaccination hesitancy in the United States: a rapid national assessment. J Community Health. 2021;46(2):270–277. https://doi.org/10.1007/s10900-020-00958-x.
9. Callaghan T, Moughtaderi A, Lueck JA, et al. Correlates and disparities of intention to vaccinate against COVID-19. Soc Sci Med. 2021;272:113638. https://doi.org/10.1016/j.socscimed.2020.113638.
10. KFF COVID-19 vaccine monitor: February 2021. KFF. Published February 26 https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-february-2021/; 2021. Accessed May 19, 2021.
11. Fisher KA, Bloomstone SJ, Walder J, Crawford F, Fouayzi H, Mazor KM. Attributes toward a potential SARS-CoV-2 vaccine: a survey of U.S. Adults. Ann Intern Med. 2020;173(12):946–973. https://doi.org/10.7326/M20-3569.
12. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020;26:100495. https://doi.org/10.1016/j.eclinm.2020.100495.
13. Iadarola S, Siegel JF, Gao Q, McGrath K, Bonuck KA. COVID-19 vaccine perceptions in New York state’s intellectual and developmental disabilities.
